Compare YOUL & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YOUL | GANX |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | China | United States |
| Employees | 424 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.0M | 76.4M |
| IPO Year | N/A | 2021 |
| Metric | YOUL | GANX |
|---|---|---|
| Price | $0.45 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 1.8M | 654.5K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $1.41 |
| 52 Week High | $4.40 | $4.34 |
| Indicator | YOUL | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 55.83 |
| Support Level | $0.38 | $1.73 |
| Resistance Level | $1.06 | $2.12 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 16.91 | 68.09 |
Youlife Group Inc is a blue-collar lifetime service platform in China, dedicated to serving the needs throughout the entire life cycle of the blue-collar talent. It provides blue-collar lifetime services to students, blue-collar talent, and corporate customers. Its segments are the vocational education segment, which engages in the provision of vocational education entrusted management services, self-operated vocational school services, and Others; the HR recruitment segment engages in the provision of HR recruitment services regarding blue-collar talent to customers; the employee management segment engages in the provision of labor outsourcing services, labor dispatch services and others; and the market service segment engages in the provision of value-added services.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.